Definium Therapeutics, Inc. is rated a Strong Buy due to upcoming pivotal clinical trial results expected in 2026, including phase 3 data for DT120 ODT targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD), and phase 2a data for DT402 aimed at adult autism spectrum disorder (ASD). DT402 is notable for addressing a significant unmet need with a differentiated R(-)-MDMA profile and prior phase 1 safety data. The company holds $411.6 million in cash, ensuring no near-term funding concerns and positioning it well to advance through multiple clinical milestones through 2028.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Bunker Hill Mining Corp. has appointed Bradley Barnett as permanent CFO and Mark Hayes as General Counsel to support its transition to commercial production at the historic Bunker Hill Mine in Idaho. The company also achieved an improved 'A' grade in...
Alaska Air Group is rated Buy with a $60 fair value, reflecting confidence that recent losses are due to temporary fuel cost shocks. Despite a $193 million loss in Q1 and suspended guidance, the airline's core business segments like loyalty programs,...
UnitedHealth Group reported a strong second-quarter net income of $5.48 billion, driven by a significant reduction in medical costs. The company lowered its medical care ratio to 86.7% from 89.4% year-over-year by exiting unprofitable markets and man...
Compagnie Financière Richemont SA reported strong Q1 2027 results, driven mainly by accelerating growth in its Jewellery segment, which accounted for about 89% of sales growth and achieved double-digit increases across all regions and channels for th...
